SI2049142T1 - Formulacije kaspofungina - Google Patents

Formulacije kaspofungina

Info

Publication number
SI2049142T1
SI2049142T1 SI200731128T SI200731128T SI2049142T1 SI 2049142 T1 SI2049142 T1 SI 2049142T1 SI 200731128 T SI200731128 T SI 200731128T SI 200731128 T SI200731128 T SI 200731128T SI 2049142 T1 SI2049142 T1 SI 2049142T1
Authority
SI
Slovenia
Prior art keywords
caspofungin formulations
caspofungin
formulations
Prior art date
Application number
SI200731128T
Other languages
English (en)
Other versions
SI2049142T2 (sl
Inventor
Christian Welz
Gottfried Stubauer
Andreas Schmarda
Herwig Jennewein
Ingolf Macher
Johannes Ludescher
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38691922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2049142(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SI2049142T1 publication Critical patent/SI2049142T1/sl
Publication of SI2049142T2 publication Critical patent/SI2049142T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
SI200731128T 2006-07-26 2007-07-24 Formulacije kaspofungina SI2049142T2 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06117886 2006-07-26
EP07109723 2007-06-06
EP07819912.2A EP2049142B2 (en) 2006-07-26 2007-07-24 Caspofungin formulations
PCT/EP2007/057623 WO2008012310A1 (en) 2006-07-26 2007-07-24 Caspofungin formulations

Publications (2)

Publication Number Publication Date
SI2049142T1 true SI2049142T1 (sl) 2013-02-28
SI2049142T2 SI2049142T2 (sl) 2016-04-29

Family

ID=38691922

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731128T SI2049142T2 (sl) 2006-07-26 2007-07-24 Formulacije kaspofungina

Country Status (11)

Country Link
US (2) US8232245B2 (sl)
EP (2) EP2340846A1 (sl)
JP (1) JP5373606B2 (sl)
KR (1) KR101536781B1 (sl)
BR (1) BRPI0715113A2 (sl)
CA (1) CA2657817C (sl)
ES (1) ES2401299T5 (sl)
HR (1) HRP20130109T4 (sl)
PL (1) PL2049142T5 (sl)
SI (1) SI2049142T2 (sl)
WO (1) WO2008012310A1 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008269140A1 (en) * 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
ES2462090T5 (es) * 2008-06-16 2017-07-12 Pfizer Inc. Nanopartículas poliméricas cargadas de fármaco y procedimientos de fabricación y uso de las mismas
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
WO2009158034A1 (en) * 2008-06-25 2009-12-30 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Caspofungin free of caspofungin impurity a
US20100256074A1 (en) * 2008-06-25 2010-10-07 Chaim Eidelman Processes for preparing high purity aza cyclohexapeptides
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) * 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
WO2010108637A1 (en) * 2009-03-27 2010-09-30 Axellia Pharmaceuticals Aps Crystalline compound
AR079127A1 (es) * 2009-11-23 2011-12-28 Cubist Pharm Inc Composiciones de daptomicina y metodos relacionados
ES2721898T3 (es) 2009-12-11 2019-08-06 Pfizer Formulaciones estables para liofilizar partículas terapéuticas
EA201290499A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Композиции терапевтических полимерных наночастиц с высокой температурой стеклования и высокомолекулярными сополимерами
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
AU2011304408B2 (en) * 2010-09-20 2015-01-15 Xellia Pharmaceuticals Aps Caspofungin composition
CN103180336B (zh) * 2010-09-28 2016-06-15 中化帝斯曼制药有限公司荷兰公司 用于分离环六肽的方法
CN102746384B (zh) * 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
BR112015005940A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
ES2607646T3 (es) * 2012-11-20 2017-04-03 Fresenius Kabi Usa, Llc Formulaciones de acetato de caspofungina
US20140256638A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
KR20140123782A (ko) * 2013-04-15 2014-10-23 에스케이케미칼주식회사 카스포펀진 및 완충제를 포함하는 안정성이 개선된 약학적 조성물
WO2015052115A1 (en) 2013-10-07 2015-04-16 Galenicum Health S.L. Stable pharmaceutical formulations of caspofungin
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
US9675659B2 (en) 2015-08-21 2017-06-13 Trilogy Therapeutics, Inc. Methods of treating lung infection with caspofungin
KR101875512B1 (ko) 2017-05-25 2018-07-06 이병돈 손잡이 각도가 조절되는 웨이트 트레이닝기구
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
EP4051285A4 (en) * 2019-10-28 2023-12-06 Brillian Pharma Inc. PHARMACEUTICAL UNIT DOSE SYSTEMS FOR ORAL DRY SOLUTION AND SUSPENSION
JP2023517926A (ja) 2020-03-12 2023-04-27 バクスター・インターナショナル・インコーポレイテッド ソルビトールとマンニトールの組み合わせを含むダプトマイシン製剤
EP4364566A1 (en) * 2022-11-04 2024-05-08 B. Braun Melsungen AG Anti-fungal composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5552521A (en) 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
PE63998A1 (es) 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
HRP970318B1 (en) * 1996-06-14 2002-06-30 Merck & Co Inc A process for preparing certain aza cyclohexapeptides
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
WO2006117565A2 (en) † 2005-05-04 2006-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP1785432A1 (en) 2005-11-15 2007-05-16 Sandoz AG Process and intermediates for the synthesis of caspofungin.

Also Published As

Publication number Publication date
WO2008012310A1 (en) 2008-01-31
KR101536781B1 (ko) 2015-07-14
CA2657817C (en) 2016-05-31
JP2009544662A (ja) 2009-12-17
KR20090046865A (ko) 2009-05-11
EP2340846A1 (en) 2011-07-06
US20090170753A1 (en) 2009-07-02
HRP20130109T1 (en) 2013-03-31
PL2049142T5 (pl) 2016-09-30
PL2049142T3 (pl) 2013-06-28
CA2657817A1 (en) 2008-01-31
US8232245B2 (en) 2012-07-31
JP5373606B2 (ja) 2013-12-18
ES2401299T3 (es) 2013-04-18
EP2049142B1 (en) 2012-12-12
US20130028940A1 (en) 2013-01-31
HRP20130109T4 (hr) 2016-05-20
ES2401299T5 (es) 2016-04-06
EP2049142B2 (en) 2016-01-20
BRPI0715113A2 (pt) 2013-06-04
SI2049142T2 (sl) 2016-04-29
EP2049142A1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
HRP20130109T1 (en) Caspofungin formulations
GB2435419B (en) Formulations
EP2046930A4 (en) FORMULATIONS BASED ON RHAMNOLIPIDS
EP1988922A4 (en) PROTEIN FORMULATIONS
GB0605780D0 (en) Formulations
ZA200901666B (en) Fillings
AU314032S (en) Chair
EP2017283A4 (en) Peptides
GB0618697D0 (en) Formulations
AU313434S (en) Chair
GB0610336D0 (en) Formulations
AU314031S (en) Chair
IL198160A0 (en) Pharmaceutical formulations
GB0618748D0 (en) Peptide
GB0718404D0 (en) Formulations
GB0605774D0 (en) Peptide
GB0611519D0 (en) Formulations
GB0603981D0 (en) Tissue-adhesive formulations
GB0603380D0 (en) Formulations
GB0623791D0 (en) Formulations
GB0618691D0 (en) Formulations
ZA200607041B (en) Intramammary formulations
GB0615461D0 (en) Pharmaceutical formulations
AU307800S (en) Chair
AU313433S (en) Chair